Quantum BioPharma Ltd. (NASDAQ: QNTM) has added Kevin Malone as an advisor to its Board of Directors, bringing over 40 years of financial expertise to the biopharmaceutical company. Malone, founder of Malone Wealth, is recognized for his commitment to financial literacy and advocacy against market trading manipulation.
With a background deeply rooted in wealth management, Malone has established himself as a prominent voice in challenging unethical financial practices. His focus on market pattern recognition and opposition to naked short selling resonates with Quantum BioPharma’s core values of shareholder protection.
The appointment comes as Quantum BioPharma continues to develop innovative therapeutic solutions. The company’s current portfolio includes research into neurodegenerative and metabolic disorders, with a particular emphasis on its lead compound Lucid-MS, which has shown potential in preventing and reversing myelin degradation associated with multiple sclerosis.
In addition to its medical research, Quantum BioPharma maintains strategic investments through its subsidiary, FSD Strategic Investments Inc. The company has also developed UNBUZZD™, an over-the-counter product spun out to Celly Nutrition Corp., in which Quantum BioPharma retains a 25.71% ownership stake and receives royalty payments.
Malone’s expertise is expected to provide valuable insights into financial strategy and market dynamics, potentially enhancing the company’s approach to investment and shareholder engagement.
This news story relied on a press release distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Quantum BioPharma Strengthens Board with Anti-Corruption Financial Expert Kevin Malone.